Search global stocks & ETFs...Ctrl K
Learn Mode
SRPT
Stock Profile
08-05
Recommended Metric
Score Card
Explore Scores Tab
2.48
Bad
Valuation Score
Key Score
2.00
Bad
Management
1.00
Very Bad
Growth
5.00
Very Good
Profitability
2.00
Bad
Fin. Health
1.00
Very Bad
Dividends
--
--
Analyst
2.00
Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending Jun 28, 2027
Current
$17.20
Baseline
High
$39.90
▲
132.04%
Avg
$22.82
▲
32.73%
Low
$5.05
▼
-70.63%
Analyst Ratings based on 34 Analysts
Strong Buy
721%
Buy
618%
Hold
1544%
Sell
515%
Strong Sell
103%
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 835 full-time employees. The firm is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. The company has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The firm has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.Read More